Patients with genetic emphysema should have access restored, by the end of next week, to a drug withheld for more than a month in a row over who should pay to administer it.

The decision not to reimburse people for a drug shown to slow the progress of genetic emphysema has been formally communicated by the HSE to the foundation representing patients affected.